Clinical Significance of Naturally Occurring Anti‐Zona Pellucida Antibodies in Infertile Women

Michael R. Caudle, Charles A. Shivers, Robert A. Wild
In: American Journal of Reproductive Immunology and Microbiology · 1987 · vol. 15(4) , pp. 119–121 · doi:10.1111/j.1600-0897.1987.tb00001.x · W4412577633
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This study found that 33% of infertile women with anti-zona pellucida antibodies conceived after treatment for other fertility issues, suggesting these antibodies should not prevent such treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ABSTRACT Although implicated in the etiology of unexplained infertility, a primary role for antibodies to zona pellucida antigens remains uncertain. We therefore prospectively studied 21 infertility patients found to have significant anti‐zona pellucida antibody titers (1:4 to 1:16). When treated for endometriosis or other concurrent fertility problems, 7 of the 21 (33%) delivered viable infants. Two other patients conceived without treatment. Decreases in anti‐zona antibody titers were found in most but not all women with successful outcomes. In a given individual, anti‐zona antibodies may coexist with other fertility disorders. Therefore, these antibodies should not preclude treatment of concurrent fertility disorders.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK